TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23200980

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with high-grade lesions (PanIN-3 and high-grade IPMN).
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with intermediate-grade IPMNs.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with PanIN-2 lesions.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with high-grade IPMNs.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with PanIN-3 lesions.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from patients with invasive pancreatic adenocarcinomas.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Detection of mutant TP53 in duodenal samples of secretin-stimulated pancreatic juice from controls.
Number of subjects: 180
Study: 23201699

Group type: EXPERIMENTAL
Intervention: High β-palmitate formula (HBP group, n=14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low β-palmitate formula (LBP group, n=8)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Breast-fed (BF group, n=14)
Number of subjects: 36
Study: 23201707

Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsions (FOE)
Number of subjects: 6
Study: 23204083

Group type: EXPERIMENTAL
Intervention: Placement of resin-based composite restorations
Number of subjects: 172
Study: 23204247

Group type: EXPERIMENTAL
Intervention: Microaneurysm (MA) turnover calculated using RetmarkerDR
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Microaneurysm (MA) turnover predictive values
Number of subjects: 410
Study: 23205612

Group type: EXPERIMENTAL
Intervention: SRT501 (resveratrol) with bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23207683

Group type: EXPERIMENTAL
Intervention: Image-guided robotic surgery using preoperative CT-angiography
Number of subjects: 12
Study: 23207876

Group type: EXPERIMENTAL
Intervention: Losartan (0.44-2.23 mg/kg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Enalapril (0.07-0.72 mg/kg/day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study: 23208080

Group type: EXPERIMENTAL
Intervention: RV automated systolic index (RV-ASI) obtained from semi-automated border detection using 2D echocardiography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV-ASI cut-off value of 52 %
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inter-observer variability
Number of subjects: 40
Study: 23208833

Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg administered nasogastrically or nasoenterically every 12 hours
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oseltamivir carboxylate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Patients receiving ECMO
Number of subjects: 13
Study: 23209861

Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT)
Number of subjects: 629
Study: 23210427

Group type: EXPERIMENTAL
Intervention: Five gene predictive model (CLDND1, LRRN3, MUC1, GOPC, LEF1)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Five gene predictive model
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cotinine model (threshold of 10 ng/ml)
Number of subjects: 209
Study: 23210876

Group type: EXPERIMENTAL
Intervention: Misago self-expanding nitinol stent
Number of subjects: 744
Study: 23211576

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 477
Study: 23211708

Group type: EXPERIMENTAL
Intervention: Intratendinous leukocyte-rich PRP injection
Number of subjects: 25
Study: 23211938

Group type: EXPERIMENTAL
Intervention: Oral ridaforolimus (40 mg QD × 5 days/week)
Number of subjects: 147
Study: 23212516

Group type: EXPERIMENTAL
Intervention: Hu-Mikβ1 (humanized mAb directed at IL-2/IL-15Rβ subunit, CD122)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous murine Mikβ1
Number of subjects: 0
Study: 23212718

Group type: EXPERIMENTAL
Intervention: 325-mg immediate release aspirin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 325-mg enteric coated aspirin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 81 mg low-dose enteric coated aspirin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel
Number of subjects: 400

Group type: COMPARATOR
Intervention: Immediate release aspirin
Number of subjects: 400
Study: 23213069

Group type: EXPERIMENTAL
Intervention: belimumab 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: belimumab 4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 23213092

Group type: EXPERIMENTAL
Intervention: (124)I-girentuximab PET/CT
Number of subjects: 195

Group type: COMPARATOR
Intervention: CECT
Number of subjects: 195
Study: 23213094

Group type: EXPERIMENTAL
Intervention: Foretinib 240 mg once per day on days 1 through 5 every 14 days (intermittent arm)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Foretinib 80 mg daily (daily dosing arm)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Presence of germline MET mutation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Adverse events associated with foretinib
Number of subjects: 74
Study: 23214115

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study: 23215555

Group type: EXPERIMENTAL
Intervention: Chromosomal microarray analysis
Number of subjects: 4406

Group type: COMPARATOR
Intervention: Karyotyping
Number of subjects: 4406
Study: 23215909

Group type: EXPERIMENTAL
Intervention: High maternal prepregnancy body mass index (BMI)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: High BMI and high gestational weight gain (GWG)
Number of subjects: 718
Study: 23216571

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg) and Clopidogrel (600 mg) administered prior to PPCI
Number of subjects: 48
Study: 23216716

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU in the morning and afternoon for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23216781

Group type: EXPERIMENTAL
Intervention: Drug-eluting beads delivering irinotecan (DEBIRI)
Number of subjects: 3
Study: 23216798

Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone/formoterol
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Budesonide/formoterol
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol
Number of subjects: 1017
Study: 23216870

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO; a slow subcutaneous infusion via portable pump)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Oral chelation
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Combination therapy (DFO and oral chelation)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to chelation
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Ferritin iron levels
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Concerns about treatment
Number of subjects: 371
Study: 23216959

Group type: EXPERIMENTAL
Intervention: Custom-made functional insoles
Number of subjects: 119

Group type: COMPARATOR
Intervention: Prefabricated insoles
Number of subjects: 119
Study: 23217037

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) tablets (20mg artemether and 120mg lumefantrine)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Adverse effects observed in patients receiving AL
Number of subjects: 43
Study: 23217273

Group type: EXPERIMENTAL
Intervention: Oral lenalidomide (5 to 10 mg/day)
Number of subjects: 15
Study: 23217964

Group type: EXPERIMENTAL
Intervention: AZD5213 (0.05-30 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AZD5213 (1-14 mg/d)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AZD5213
Number of subjects: 7
Study: 23219031

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-deoxy-glucose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ICA-105665
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Imepitoin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NAX 801-2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tonabersat
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Valnoctamide
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sec-propylbutylacetamide (SPD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VX-765
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: YK3089
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retigabine (ezogabine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NAX 810-2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SPD
Number of subjects: 100
Study: 23221961

Group type: EXPERIMENTAL
Intervention: HEPHAISTOS orthosis
Number of subjects: 11
Study: 23222254

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (education, reminders, local opinion leaders, implementation teams)
Number of subjects: 1320
Study: 23222363

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study: 23222688

Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Number of subjects: 0
Study: 23222738

Group type: EXPERIMENTAL
Intervention: Pathology panel agreement on ISHLT grades
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Grade assignment by pathologists
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: 2004 revision of ISHLT grading scheme
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: EMB grade ≥2R
Number of subjects: 937
Study: 23222881

Group type: EXPERIMENTAL
Intervention: L-PGDS in severe obstructive sleep apnoea (n = 23)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment for 2 days in severe obstructive sleep apnoea (n = 12)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Morning urinary L-PGDS concentrations
Number of subjects: 64
Study: 23223100

Group type: EXPERIMENTAL
Intervention: Prototype NIRS monitor
Number of subjects: 70

Group type: COMPARATOR
Intervention: Personal computer-based COx
Number of subjects: 70
Study: 23223434

Group type: EXPERIMENTAL
Intervention: 53 single-nucleotide polymorphisms (SNPs) identified as significant predictors of inhibitor status after adjustment for potential confounders.
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: 8 of the 53 SNPs were significant predictors among the discordant pairs.
Number of subjects: 833
Study: 23224059

Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Preeclampsia during pregnancy
Number of subjects: 234
Study: 23225085

Group type: EXPERIMENTAL
Intervention: Pretreatment TARC levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TARC levels
Number of subjects: 0
Study: 23225523

Group type: EXPERIMENTAL
Intervention: Preendoscopy treatment
Number of subjects: 2660

Group type: EXPERIMENTAL
Intervention: Postendoscopic pharmacological therapy
Number of subjects: 2660

Group type: EXPERIMENTAL
Intervention: Therapeutic procedures during endoscopy
Number of subjects: 2660

Group type: EXPERIMENTAL
Intervention: Healthcare resource consumption
Number of subjects: 2660

Group type: EXPERIMENTAL
Intervention: Time from admission to endoscopy
Number of subjects: 2660
Study: 23225902

Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara (MVA)
Number of subjects: 151
Study: 23226015

Group type: EXPERIMENTAL
Intervention: Treated exacerbations (n = 164)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exacerbation length (determined for 17 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Treatment delay
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Time to resolution of exacerbation after treatment initiation
Number of subjects: 23
Study: 23226204

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg PO twice daily) plus carboplatin (AUC=6) and paclitaxel (225 mg/m(2)) administered IV on day 1 for up to 6 cycles, followed by sorafenib monotherapy until disease progression
Number of subjects: 25
Study: 23227182

Group type: EXPERIMENTAL
Intervention: Metabolomic analysis using a combined direct injection and LC-MS/MS assay (AbsolutIDQ p180 kit)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Neonates with Hypoxic ischaemic encephalopathy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Both study groups (HIE and asphyxiated infants)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Logistic regression model using 5 metabolites
Number of subjects: 142
Study: 23228035

Group type: EXPERIMENTAL
Intervention: R115777 administered twice per day for 21 days of a 28-day cycle.
Number of subjects: 14
Study: 23228045

Group type: EXPERIMENTAL
Intervention: DA-EDOCH14-R (two-weekly dose-adjusted EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DA-EDOCH14-R
Number of subjects: 20

Group type: COMPARATOR
Intervention: DA-EPOCH-R (3-weekly DA-EPOCH-R)
Number of subjects: 20

Group type: COMPARATOR
Intervention: DA-EPOCH-R
Number of subjects: 20
Study: 23228190

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD) combined with cisplatin (60 mg/m(2) d1 q 3w) and capecitabine (1250 mg/m(2) bid d1-14 q 21)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD) combined with cisplatin (50 mg/m(2) d1 q 2w) and 5-fluoruracil (2 g/m(2) d1, q 1w)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imatinib (300 mg QD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imatinib (700 mg QD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg QD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard therapy (not specified)
Number of subjects: 35
Study: 23228299

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23228446

Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, and Sunitinib (GCS)
Number of subjects: 45
Study: 23228990

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day combined with docetaxel at 30 mg/m(2) for 3 of every 4 weeks.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day
Number of subjects: 34
Study: 23229679

Group type: EXPERIMENTAL
Intervention: Thymoma patients (15 patients)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy controls (15 patients)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Thymoma patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Thymoma type B2 patients
Number of subjects: 87
Study: 23229692

Group type: EXPERIMENTAL
Intervention: Eyes with optic disc hemorrhages (DH)
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: Eyes with 2 or more optic disc hemorrhages (DH)
Number of subjects: 2607

Group type: COMPARATOR
Intervention: Eyes initially randomized to treatment
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: Eyes with recurrent optic disc hemorrhages (DH)
Number of subjects: 2607
Study: 23229696

Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG (24-hour IOP monitoring)
Number of subjects: 40
Study: 23229886

Group type: EXPERIMENTAL
Intervention: Algenpantucel-L immunotherapy in addition to gemcitabine and 5-fluorouracil-based chemoradiotherapy
Number of subjects: 70
Study: 23230059

Group type: EXPERIMENTAL
Intervention: Oseltamivir 3.0 mg/kg for infants 0-8 months
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Oseltamivir 3.5 mg/kg for subjects 9-11 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: FDA-approved unit dose of 30 mg for subjects 12-23 months
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 87
Study: 23230457

Group type: EXPERIMENTAL
Intervention: Early intensive systolic blood pressure (BP) lowering for acute hypertension in ICH patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicenter study for hyperacute BP lowering (the SAMURAI-ICH study)
Number of subjects: 0
Study: 23231599

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study: 23232038

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25-100 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 100 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) (all doses)
Number of subjects: 0
Study: 23232250

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté
Number of subjects: 1282
Study: 23232587

Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (96th percentile)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (94th percentile)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: CDC BMI percentile (95th percentile)
Number of subjects: 369
Study: 23233047

Group type: EXPERIMENTAL
Intervention: High MSI2 expression
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NUMB expression
Number of subjects: 454
Study: 23233387

Group type: EXPERIMENTAL
Intervention: On-site HV measurement using ABC/2 method
Number of subjects: 56

Group type: COMPARATOR
Intervention: Central HV measurement using ABC/2 method
Number of subjects: 56

Group type: COMPARATOR
Intervention: MIPAV HV measurement
Number of subjects: 56
Study: 23233538

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23233571

Group type: EXPERIMENTAL
Intervention: Salvage therapy (specific regimens not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-resolution genomic analyses of matched pairs of diagnostic and relapse bone marrow samples
Number of subjects: 0
Study: 23233718

Group type: EXPERIMENTAL
Intervention: (90)Yttrium-ibritumomab-tiuxetan ((90)YIT)
Number of subjects: 59
Study: 23234268

Group type: EXPERIMENTAL
Intervention: ReCap Hip Resurfacing System implant (Biomet Inc., Warsaw, USA)
Number of subjects: 240
Study: 23234514

Group type: EXPERIMENTAL
Intervention: Expanded cord blood with mesenchymal stromal cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: Unmanipulated cord blood
Number of subjects: 31
Study: 23235268

Group type: EXPERIMENTAL
Intervention: Abbreviated 7-item Quality of Life Scale (QLS)
Number of subjects: 1460
Study: 23236082

Group type: EXPERIMENTAL
Intervention: Intervention condition (not specified)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Having a boyfriend
Number of subjects: 701
Study: 23236375

Group type: EXPERIMENTAL
Intervention: Sepsis patients (n=15)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SIRS patients (n=13)
Number of subjects: 42
Study: 23237128

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies during hospitalization and after discharge
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Initial combinations of antithrombotic therapies during hospitalization
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Changes in antithrombotic treatments during 24-month follow-up
Number of subjects: 10568
Study: 23237982

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 482
Study: 23238591

Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11 (rhIL-11, Neumega®)
Number of subjects: 9
Study: 23238660

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Screening Algorithm
Number of subjects: 400
Study: 23238879

Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: K-RAS mutations
Number of subjects: 44
Study: 23239552

Group type: EXPERIMENTAL
Intervention: Right hepatic lobectomy
Number of subjects: 12
Study: 23240851

Group type: EXPERIMENTAL
Intervention: Topotecan delivered via convection-enhanced delivery (CED) at a total dose of 0.403 mg in 6.04 ml over 100 hours for the first patient, and 0.284 mg in 5.30 ml over 100 hours for the second patient.
Number of subjects: 2
Study: 23241251

Group type: EXPERIMENTAL
Intervention: Guggulsterone (oral administration)
Number of subjects: 15
Study: 23241455

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs supplementation (1.14 g DHA and 1.56 g EPA from six fish oil capsules per day for twelve weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs supplementation
Number of subjects: 20
Study: 23242239

Group type: EXPERIMENTAL
Intervention: Feedback interventions to improve prescribing safety data (two active arms)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 262
Study: 23242479

Group type: EXPERIMENTAL
Intervention: Self-rated activity relative to others' age, 5-point Likert Scale
Number of subjects: 3410

Group type: EXPERIMENTAL
Intervention: Relative activity
Number of subjects: 3410

Group type: EXPERIMENTAL
Intervention: Health-predictor associations with age
Number of subjects: 3410
Study: 23242596

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks
Number of subjects: 42
Study: 23242601

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with MTX/IFO/DEP followed by high-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with MTX/IFO/DEP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with AraC/TT/DEP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with HD-ASCT
Number of subjects: 30